Ascentage Pharma Group International Announces Regulatory Review for Lisaftoclax in China Following New Drug Application Submission

Reuters
2025.05.23 00:16
portai
I'm PortAI, I can summarize articles.

Ascentage Pharma Group International has announced the regulatory review of its new drug application for lisaftoclax in China. This Bcl-2 inhibitor shows promise in treating difficult myeloid malignancies, with potential approval making it the second Bcl-2 inhibitor globally. The submission highlights Ascentage's dedication to innovative therapies for patients with limited options.

Ascentage Pharma Group International has recently announced the submission of a new drug application for lisaftoclax in China, marking a significant milestone in the program's progress. This novel Bcl-2 inhibitor has demonstrated antitumor activity in both previously untreated patients and those treated with venetoclax, addressing critical treatment gaps in difficult-to-treat myeloid malignancies. If approved, lisaftoclax would be the second Bcl-2 inhibitor to receive approval globally. This regulatory submission underscores Ascentage Pharma's commitment to developing innovative therapies for patients with limited treatment options.

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.